secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001804220-24-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%
---------------------------------------------------------------------------

- Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).
- Non-GAAP diluted EPS $12.46 (up 8%); includes $0.43 unfavorable IPR&D charge.
- Dupixent global net sales $3.82B (+23%, recorded by Sanofi); EYLEA HD+EYLEA US $1.54B (+3%).
- FDA approved Dupixent for COPD in Sept. 2024; positive Phase 3 data for CSU and bullous pemphigoid.
- FY 2024 guidance updated: GAAP R&D $5.055-5.145B, SG&A $2.93-3.02B; share repurchases $738M in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422024000038/0001804220-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422024000038/regn-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001804220-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer